HER2-mutated non-small-cell lung cancer (NSCLC) is a rare form of lung cancer where the cancer cells have a mutation that makes them grow and divide in an uncontrolled way. You can best understand ...

Sabari, MD, discusses the depth and durability of response to zongertinib in patients with HER2 mutation–positive non–small ...

Researchers headed by a team at Keck Medicine of USC have found that corticosteroids, which are commonly prescribed to non-small cell lung cancer (NSCLC) patients to alleviate cancer-related symptoms, ...

Three-fourths of patients had cancer-free mediastinal lymph nodes, clear surgical margins ...

FDA‑approved zongepanib transforms HER2‑mutant NSCLC, delivering ~77% responses with less toxicity than chemo.

Immune checkpoint inhibitors (ICI) are a cornerstone of non-small cell lung cancer (NSCLC) treatment, but it’s not clear whether adding chemotherapy to ICI — a common practice with younger patients ...

The FDA has accepted the NDA for zipalertinib to treat adult patients with locally advanced or metastatic EGFR exon 20 insertion-mutated NSCLC.

The FDA has listed two HER2-mutant non-small cell lung cancer therapies—zongertinib and sevabertinib—under accelerated approval with required confirmatory trials to verify clinical benefit. Both drugs ...

The Business Research Company's Non-Small Cell Lung Cancer (NSCLC) Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 Non-Small Cell Lung Cancer (NSCLC) Global Market ...

NSCLC is the most frequent histological subtype of lung cancer, accounting for approximately 85% of patients with lung cancer. NSCLC includes a variety of different lung cancers, most notably ...